Growth Metrics

Adaptive Biotechnologies (ADPT) Income from Continuing Operations (2018 - 2025)

Historic Income from Continuing Operations for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $9.5 million.

  • Adaptive Biotechnologies' Income from Continuing Operations rose 12973.8% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$79.6 million, marking a year-over-year increase of 5925.41%. This contributed to the annual value of -$159.6 million for FY2024, which is 2916.46% up from last year.
  • Per Adaptive Biotechnologies' latest filing, its Income from Continuing Operations stood at $9.5 million for Q3 2025, which was up 12973.8% from -$25.6 million recorded in Q2 2025.
  • In the past 5 years, Adaptive Biotechnologies' Income from Continuing Operations ranged from a high of $9.5 million in Q3 2025 and a low of -$69.5 million during Q4 2023
  • Moreover, its 5-year median value for Income from Continuing Operations was -$47.5 million (2024), whereas its average is -$44.1 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first plummeted by 7293.68% in 2023, then skyrocketed by 12973.8% in 2025.
  • Adaptive Biotechnologies' Income from Continuing Operations (Quarter) stood at -$61.4 million in 2021, then surged by 34.53% to -$40.2 million in 2022, then tumbled by 72.94% to -$69.5 million in 2023, then skyrocketed by 51.46% to -$33.7 million in 2024, then soared by 128.31% to $9.5 million in 2025.
  • Its Income from Continuing Operations was $9.5 million in Q3 2025, compared to -$25.6 million in Q2 2025 and -$29.8 million in Q1 2025.